Molecular analyses of pancreatic cancer genomes have further revealed activating mutations in KRAS and inactivation of CDKN2A, TP53 and SMAD4, either through point mutation or copy number changes at >50% population frequency10–12. The gene discussed is CDKN2A; the disease is pancreatic neoplasm.